Background:
- Advanced urothelial carcinoma (UC) is a devastating disease, however recent advances with antibody drug conjugates (ADCs), including enfortumab vedotin (EV), have improved outcomes significantly.1,2
- Currently no biomarkers are clinically available to predict response to therapy EV.
- We hypothesized that benefit from EV may correlate with RNA expression of NECTIN4, the gene encoding the relevant cell surface antigen for EV.
- Therefore, we performed a landscape analysis of NECTIN4 in advanced UC and correlated expression with oncologic outcomes.